Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
about
Niacin for primary and secondary prevention of cardiovascular eventsTherapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studiesTriglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseDiabetes DyslipidemiaNiacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin MimeticsFamilial hypercholesterolemia: present and future managementNiacin, an old drug with a new twistLipid abnormalities in kidney disease and management strategiesNiacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?JTT-705: is there still future for a CETP inhibitor after torcetrapib?Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Seeing red: flushing out instigators of niacin-associated skin toxicity.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.The Role of PPARα Activation in Liver and Muscle.Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.Extended-release niacin acutely suppresses postprandial triglyceridemia.Niacin: the evidence, clinical use, and future directions.Niacin: another look at an underutilized lipid-lowering medication.Raising HDL cholesterol in women.Niacin for primary and secondary prevention of cardiovascular events.Atherosclerosis in type 2 diabetes: a role for fibrate therapy?Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression.Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouseLow incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.A Grape Seed Procyanidin Extract Ameliorates Fructose-Induced Hypertriglyceridemia in Rats via Enhanced Fecal Bile Acid and Cholesterol Excretion and Inhibition of Hepatic Lipogenesis.NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the NucleusJBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Mixed dyslipidemias in primary care patients in France.Best practice in primary care pathology: review 7.Therapeutic use of the high-density lipoprotein protein and peptides.FIELD study.Lipid-lowering effects of statins: a comparative review.
P2860
Q24203613-D4F6D3F3-EAC4-48E8-8D11-FDEEA1F80883Q26738588-0FE5F829-0066-469B-83E3-55E7DA36E6D6Q26745946-76FD0BAC-AE2D-4799-83B2-CB1775D5BA93Q26750905-60EC2447-C7AA-48E3-A59E-B0D2621C6119Q26765137-FE67DCFB-152E-499B-B3AC-CB8345DD117DQ26828489-A0A8269C-DD97-46DB-947D-EB754BD491E6Q27002774-F0783E24-9AA1-4D9C-9C09-CE71E0083B0DQ27024982-519A29CA-3DCB-4746-A8C1-C4079E761526Q28086787-9F363DA5-43E8-49FB-91EF-56479E53949BQ28200554-C5F4118F-AC31-499F-984A-97314827B9BCQ28222549-E5B68E61-869F-475C-80D4-35BD169733CFQ28294797-AF4675D0-B92C-4E43-A451-D8E4DC2916A3Q33590777-687DA37E-F4FD-46E0-B37C-ED171B333121Q33757845-7A8512BD-02A8-42BB-A364-589A1185177AQ33765072-016C5FE1-D1E1-47E8-8848-E57A29F28415Q33933632-A1E4229F-611E-490D-9F78-94B8A8FEFD04Q33993233-318A995A-FE36-4C86-96E3-C04E1C1A9552Q34028776-48117966-02EB-487E-8141-3A0C0CAF502FQ34068746-354A8E90-F30F-4C3E-AF6D-1DAEB0418E86Q34106233-F2387C2D-84DA-499C-9BF3-0DC39F6896DAQ34179056-BA5B0F52-7565-4FE1-92C7-5240DA82DF41Q34223452-CCA525CC-29E9-47A3-A81E-365425814371Q34228636-28AF927C-3BE7-42DC-A33A-D8D3111E3024Q34255686-E6A8BBD9-EA52-4EE6-9241-41E4569DB337Q34271942-5521F118-5C0D-4AAA-A37B-C04D1D11AB95Q34682221-7F361FDE-5967-4D3F-9BF4-0DB346CA9E89Q34730108-E03C315F-AB94-4BA5-AE9D-86E609203F43Q34805517-32CA1534-8C2E-49BD-92FA-CA4290687111Q35034986-53339F2F-7B5E-4FE0-B0B9-0476C7E1F502Q35146964-1C4D352E-A64B-4608-BBF4-EDAD43629291Q35498269-1019C146-40C8-4659-9D0C-5B3FBC528979Q35650429-B5D1611D-3D99-431A-A2D3-3FB8AF7C5593Q35803459-5FAA250C-5DB8-4A5D-A18C-4E081D9130C4Q35805959-4F14C5C3-4B38-47D4-A618-69AA02A8AC80Q35808362-12FD534D-F1C0-4EF5-B42E-85CFE46E21E4Q35940449-A11D5379-5BE8-4F01-931E-AB2DCB06AE9FQ36014419-E2AC4409-BA53-4951-918F-CE236E72649DQ36407298-170B8311-BE0F-4232-B268-A2317A745A26Q36522005-B848A6CC-4D76-459B-A249-10400E2143FCQ36573878-3040BACE-169E-4218-BAEF-646C76DC6278
P2860
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Efficacy and safety of high-de ...... randomized controlled trials.
@ast
Efficacy and safety of high-de ...... randomized controlled trials.
@en
type
label
Efficacy and safety of high-de ...... randomized controlled trials.
@ast
Efficacy and safety of high-de ...... randomized controlled trials.
@en
prefLabel
Efficacy and safety of high-de ...... randomized controlled trials.
@ast
Efficacy and safety of high-de ...... randomized controlled trials.
@en
P2093
P1476
Efficacy and safety of high-de ...... randomized controlled trials.
@en
P2093
Barbara A Hutten
Erik S G Stroes
John J P Kastelein
Rakesh S Birjmohun
P304
P356
10.1016/J.JACC.2004.10.031
P407
P577
2005-01-01T00:00:00Z